Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors

Gene Therapy

Volumn 5, Issue 10, 1998, Pages 1400-1409

  Addison, C L ^a,b   Bramson, J L ^a,c   Hitt, M M ^a   Muller, W J ^a   Gauldie, J ^a   Graham, F L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Inex Pharmaceuticals   (Canada)

Author keywords

Adenovirus; Cancer; Cytokines; Gene therapy; Immunotherapy

Indexed keywords

CANCER ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; FEMALE; GENE THERAPY; GENE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

EID: 0031759989     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300731     Document Type: Article

References (54)

1. Pardoll DM. Immunotherapy with cytokine gene-transduced tumor cells: the next wave in gene therapy for cancer. Curr Opin Oncol 1992; 4: 1124-1129.
2. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
3. Gilboa E, Lyerly HK, Vieweg J, Saito S. Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol 1994; 5: 409-417.
4. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
5. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704.
6. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995; 270: 908.
7. Haddada H et al. Adenoviral interleukin-2 gene transfer into P815 tumor abrogates tumorigerucity and induces antitumoral immunity in mice. Hum Gene Ther 1993; 4: 703-711.
8. Addison CL et al. Intratumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522-8526.
9. Cordier L et al. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harbouring the murine IL-2 gene. Gene Therapy 1995; 2: 16-21.
10. Toloza EM et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996; 3:11-17.
11. Addison CL, Gauldie J, Muller WJ, Graham FL. An adenoviral vector expressing interleukin-4 modulates tuinorigenicity and induces regression in a murine breast cancer model. Int J Oncol 1995; 7: 1253-1260.
12. Bramson JL et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7; 1995-2002.
13. Ceams-Spielman J, Cavender DE, Wood PJ. Interferon-gamma increases susceptibility of murine pancreatic beta cells to lysis by allogeneic cytotoxic T lymphocytes. Autoimmunity 1990; 8: 135-142.
14. Ramanathan S et al. Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats. J Immunol 1996; 157: 2209-2215.
15. Yron I, Wood TA, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 1980; 125: 238-245.
16. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon. I. Lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-1841.
17. Mule JJ, Shu S, Schwartz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487-1489.
18. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response. Cell 1990; 60: 397-103.
19. Rosenberg SA, Spiess PJ, LaFreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986; 233: 1318-1321.
20. Cameron RB, Spiess PJ, Rosenberg SA. Synergistic antitumor activity of tumor infiltrating lymphocytes, interleukin-2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 1990; 178: 1223-1230.
21. Lindgren CG, Thompson JA, Higuchi CM, Fefer A, Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4. J Immunother 1993; 14: 322-328.
22. Kobayashi M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827-845.
23. Wong HL et al. Characterization of a factor(s) which synergizes with recombinant interleukin-2 in promoting allogeneic human cytolytic T-Iymphocyte responses in vitro. Cell Immunol 1988; 111: 39-54.
24. Stern AS et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990; 87: 6808-6812.
25. Brunda MJ et al. Anti-tumor and anti-metastatic activity of interleukin-12 against murine tumors. J Exp Med 1993; 171: 249-263.
26. Nastala CL et al. Recombinant IL-12 administration induces rumor regression in association with IFN-γ production. J Immunol 1994; 153: 1697-1706.
27. Zou JP et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by antitumor T cells. Int Immunol 1995; 7: 1135-1145.
28. Chan SH et al. Induction of IFN-γ by natural killer cell stimulatory factor: characterization of the responding cells and synergy with other inducers. J Exp Med 1991; 173: 869-879.
29. Chan SH et al. Mechanisms of IFN-γ induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in synergistic interaction between NKSF and IL-2. J Immunol 1992; 148: 92-98.
30. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143: 127-142.
31. Pappo I et al. Administration of systemic or local interleukin-2 enhances the antitumor effects of interleukin-12 gene therapy. J Surg Res 1995; 58: 218-226.
32. Vagliani M et al. Interleukin-12 potentiates the curative effect of a vaccine based on interleukin-2 transduced tumor cells. Cancer Res 1996, 56: 467-470.
33. Schmidt W et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 1995; 92: 4711-4714.
34. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. In: August JT (ed). Advances in Pharmacology. Academic Press: San Diego, CA, 1997, pp 137-206.
35. Yang Y et al. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 90: 4601-1605.
36. + T cells. J Exp Med 1996,184: 19-29.
37. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
38. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but does inhibit virus dissemination. Gene Therapy 1997; 4: 1069-1096.
39. Hanagiri et al. Effects of interleukin-12 on in vitro culture with interleukin-2 of regional lymph node lymphocytes from lung cancer patients. Cancer Immunol Immunother 1996; 43: 87-93.
40. Mossman TR, Sad S. The expanding universe of T cell subsets: Thl, Th2 and more. Immunol Today 1996; 17: 138-147.
41. Gerrard TL et al. Modulation of class I and II histocompatibility antigens on human T cell lines by IFN-gamma. J Immunol 1988; 140: 3450-3455.
42. Kaplan G, Luster AD, Hancock G, Cohn Z. The expression of γ interferon-induced protein (IP-10) in delayed immune responses in human skin. J Exp Med 1987; 166: 1098-1108.
43. Farber JM. HuMIG: a new member of the CXC chemokune family of cytokines. Biochem Biophys Res Comm 1993; 192: 223-230.
44. Angiolillo AL et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 158: 155-162.
45. Luster AD, Greenberg SM, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995; 182: 219-232.
46. Strieter RM et al. The functional role of the 'ELR' motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-27357.
47. Bramson JL et al. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of a biologically active interleukin-12. Hum Gene Ther 1996; 7: 333-342.
48. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-72.
49. Louis N, Evelegh C, Graham FL. Cloning and sequencing of the cellular/viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 1997; 233: 423-429.
50. Hitt MM et al. Techniques for human adenovirus vector construction and characterization. In: Adolph KW (ed). Methods in Molecular Genetics. Academic Press: Orlando, FL, 1995, pp 13-30.
51. Guy CT, Cardiff RD, Muller WM. Induction of mammary tumors by expression of polyoma middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-961.
52. Dillworth SM, Giffin BE. Monoclonal antibodies against polyoma virus tumor antigens. Proc Natl Acad Sci USA 1982; 79: 1059-1063.
53. Davidson D, Hassell JA. Overproduction of polyomavirus middle T antigen in mammalian cells through the use of an adenovirus vector. J Virol 1987; 61: 1226-1239.
54. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996; 184: 1879-1890.